Potassium Chloride
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Potassium Chloride: From Potassium Supplementation to Renal Tubular Acidosis
One-Sentence Summary
Potassium chloride (KCl) is the standard agent used to correct potassium deficiency (hypokalemia). The TxGNN model predicts it may be effective for Renal Tubular Acidosis, but this prediction is currently supported only by mechanistic reasoning — no clinical trials or published literature were found in this evidence pack.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in the current evidence pack (no license or indication text available); KCl is generically used for potassium repletion/hypokalemia |
| Predicted New Indication | Renal Tubular Acidosis |
| TxGNN Prediction Score | 99.87% |
| Evidence Level | L4 |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this evidence pack. Based on known pharmacology, potassium chloride directly replenishes extracellular and intracellular potassium stores and is the standard supplement used wherever potassium loss or deficiency occurs.
Renal tubular acidosis (RTA) — particularly distal (Type 1) and proximal (Type 2) forms — is characterised by renal potassium wasting and persistent hypokalemia as a core feature of the disease. Correcting this hypokalemia is a well-established, guideline-level component of RTA management, typically alongside alkalinizing agents such as potassium citrate.
The mechanistic link here is therefore direct rather than speculative: KCl’s core pharmacological action (potassium repletion) matches a defining clinical need in RTA. However, this evidence pack found no registered clinical trials or peer-reviewed literature specifically evaluating KCl in RTA, so the prediction should be regarded as mechanism-supported rather than clinically validated.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
No SAHPRA registrations were found for this product in the evidence pack, and market status is recorded as not marketed in South Africa.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanistic rationale for KCl in renal tubular acidosis is strong and consistent with established clinical practice, but the complete absence of clinical trial and literature evidence, combined with missing safety/labelling data, means this cannot yet move past an initial mechanistic screen.
To proceed, the following is needed:
- TFDA/SAHPRA-equivalent product labelling (warnings, contraindications) — currently a blocking data gap
- Confirmed mechanism of action documentation from DrugBank or equivalent source
- Targeted literature and clinical trial search specifically for KCl (or potassium salts generally) in RTA management
- Confirmation of South African market/registration status for potassium chloride products
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.